A biopharmaceutical contract research organization, or CRO technology service project – being funded by Taizhou Chengtai Biotechnology Co Ltd – broke ground on April 8 in Taizhou city, in East China's Jiangsu province.
In the life sciences, a CRO is a company that provides support to the pharma, biotechnology and medical device industries in the form of research services outsourced on a contract basis.
The facility will be situated in the Taizhou Medical High-tech Zone in Taizhou city. The company that will operate it specializes in biopharma CRO and contract development manufacturing organizational, or CDMO technology services.
Its main businesses include routine peptides services, peptides fluorescent probes and peptides chemicals modification services, among others.
The company is understood to be committed to becoming a leading service provider with significant influence in the fields of peptides and oligonucleotides.
With an investment of 100 million yuan ($13.82 million), its new CRO technology service facility will be based in Building 15 in the health industry cluster in the zone's chemicals new materials industrial park.
It is expected to start operating by September, providing peptides and oligonucleotides research and development technology outsourcing services. This will be for cancer, autoimmune, metabolic and other diseases for pharmaceuticals and chemicals enterprises.
A bird's-eye view of the Taizhou Medical High-tech Zone. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]